Product image of Metlinka (Metformin Hydrochloride, Sitagliptin) supplied by GNH India

Metlinka

Active Ingredient:
Metformin Hydrochloride, Sitagliptin
Origin:
EU

Metlinka (Metformin Hydrochloride, Sitagliptin)

Metformin Hydrochloride and Sitagliptin, the active ingredient in Metlinka, is a Biguanide; DPP‑4 inhibitor presented as a tablet for oral use. It helps control blood glucose levels in adults with type 2 diabetes mellitus, often used when diet, exercise, and monotherapy are insufficient.

GNH India supplies Metlinka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for importers. Products are manufactured in EU‑approved facilities and undergo full batch release testing before distribution.

Manufacturer / TM Owner

Swyssi Ag

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Metlinka, a fixed‑dose combination of metformin and sitagliptin, is indicated for managing hyperglycemia in type 2 diabetes mellitus.

  • Type 2 diabetes mellitus: improves overall glycemic control when added to diet and exercise.
  • Inadequate control on metformin monotherapy: provides additional DPP‑4 inhibition to lower glucose.
  • Inadequate control on sitagliptin monotherapy: adds metformin to reduce hepatic glucose production.

How It Works

  • Metformin reduces hepatic gluconeogenesis and enhances peripheral insulin sensitivity, while sitagliptin inhibits the dipeptidyl peptidase‑4 enzyme, increasing endogenous incretin hormones (GLP‑1 and GIP) that promote glucose‑dependent insulin secretion and suppress glucagon release, together lowering blood glucose levels.

Side Effects

Metlinka may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Diarrhea: loose stools, often early in therapy.
  • Headache: mild cranial discomfort.
  • Upper respiratory tract infection: cold‑like symptoms.
  • Abdominal discomfort: general stomach pain.
  • Metallic taste: altered taste perception.

Serious or Rare Side Effects

  • Lactic acidosis: rare but life‑threatening metabolic disturbance.
  • Severe hypoglycemia: especially when combined with insulin or sulfonylureas.
  • Pancreatitis: inflammation of the pancreas.
  • Severe allergic reaction: rash, swelling, or anaphylaxis.
  • Hepatic dysfunction: abnormal liver enzymes.
  • Acute kidney injury: sudden loss of kidney function.

Precautions & Warnings

Before prescribing Metlinka, clinicians should evaluate patient-specific risk factors and monitor for complications.

  • Renal function: assess baseline creatinine clearance and monitor periodically.
  • Lactic acidosis risk: avoid in patients with severe renal impairment or metabolic acidosis.
  • Hypoglycemia risk: monitor closely when used with insulin or sulfonylureas.
  • Pregnancy and lactation: use only if potential benefit justifies potential risk.
  • Cardiovascular disease: monitor for heart failure symptoms.
  • Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Metlinka can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

  • Phenformin or other contraindicated biguanides: increased risk of lactic acidosis.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole): elevate sitagliptin plasma levels.
  • Iodinated contrast agents: may precipitate renal impairment when combined with metformin.

Moderate Interactions (Monitor Closely)

  • Sulfonylureas: heightened risk of hypoglycemia.
  • Diuretics (thiazides): may affect renal clearance of metformin.
  • Beta‑blockers: can mask symptoms of hypoglycemia.

Frequently Asked Questions

Metlinka is a fixed‑dose oral combination of metformin and sitagliptin indicated to improve blood glucose control in adults with type 2 diabetes mellitus, typically when diet, exercise, and single‑agent therapy are insufficient.

Metformin lowers blood glucose primarily by decreasing hepatic glucose production and enhancing peripheral insulin sensitivity, which helps cells take up glucose more efficiently without directly stimulating insulin release.

The specific dose of Metlinka is determined by the prescribing clinician based on the patient’s individual clinical profile, renal function, and response to therapy. Patients should follow the prescriber’s instructions exactly.

Safety in pregnancy and lactation has not been fully established. Metlinka should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified health professional.

To request Metlinka, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metlinka combines a Biguanide (metformin) with a DPP‑4 inhibitor (sitagliptin), offering dual mechanisms—reduced hepatic glucose output and enhanced incretin activity—whereas monotherapy agents address only one pathway. This can provide better glycemic control than either component alone for many patients.

Metlinka should be stored at ambient temperature, below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keep the container tightly closed and out of reach of children.

Metlinka is taken orally, usually once daily with a meal to reduce gastrointestinal discomfort. The tablet should be swallowed whole with water and not split, crushed, or chewed unless specifically instructed by a healthcare professional.

The most serious risks include lactic acidosis, a rare but potentially fatal metabolic condition, and severe hypoglycemia, especially when used with insulin or sulfonylureas. Patients should be educated to recognize early symptoms and seek immediate medical attention if they occur.

Metlinka is contraindicated in patients with severe renal impairment, known hypersensitivity to metformin or sitagliptin, or a history of lactic acidosis. It should also be avoided in individuals with acute or chronic metabolic acidosis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT